HBK Sorce Advisory LLC Takes $2.82 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR

HBK Sorce Advisory LLC bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 76,408 shares of the biotechnology company’s stock, valued at approximately $2,823,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after acquiring an additional 2,774,933 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 1.0% during the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock worth $47,067,000 after purchasing an additional 28,193 shares during the period. Marshall Wace LLP grew its stake in shares of Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after purchasing an additional 2,096,238 shares during the last quarter. Norges Bank purchased a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at about $30,414,000. Finally, Goldman Sachs Group Inc. raised its position in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after purchasing an additional 447,456 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Company-scheduled investor activity in January could be a near-term catalyst: a KOL webinar on Jan 6 that will feature interim clinical data for obesity programs ARO‑INHBE and ARO‑ALK7, plus a presentation at the J.P. Morgan Healthcare Conference on Jan 12. Favorable interim data or a well-received JPM presentation could boost sentiment. Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
• Neutral Sentiment: Trading activity is below the stock’s average volume today, which can mute short-term moves; fundamental balance-sheet metrics remain strong (high current/quick ratios). No corporate guidance or major deals were announced.
• Negative Sentiment: Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC filings and covered by press. Insider sales can be interpreted negatively by some investors even though the CEO retains a very large position (millions of shares) and reported reductions were small percentage changes in holdings. See SEC filings and press coverage for details. CEO Form 4 Director Form 4 Director Form 4 Director Form 4 Press: Insider Selling

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ARWR shares. Morgan Stanley lifted their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 26th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. The Goldman Sachs Group raised their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Finally, HC Wainwright increased their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $61.89.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 16,250 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the transaction, the director owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Adeoye Y. Olukotun sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the transaction, the director owned 33,600 shares of the company’s stock, valued at $2,273,376. The trade was a 22.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 368,736 shares of company stock valued at $23,670,228. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 1.2%

NASDAQ:ARWR opened at $69.83 on Wednesday. The firm’s 50-day moving average price is $49.81 and its 200-day moving average price is $32.05. The company has a market capitalization of $9.49 billion, a PE ratio of -872.77 and a beta of 1.28. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $72.36.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.